How Medicines Work in the Body

A clear, practical guide from absorption to excretion (ADME) and how drugs produce effects

Medicines are chemical tools that change how the body works — to relieve pain, fight infection, lower blood pressure, or correct biochemical imbalances. But what happens after you swallow a tablet, inhale a vapor, or receive an injection? This article explains, in straightforward terms, the journey a medicine takes through the body (absorption, distribution, metabolism, excretion — the classic “ADME”) and how drugs actually exert their effects (pharmacodynamics). We’ll also cover practical concepts clinicians use: bioavailability, half-life, steady state, drug interactions, and why people respond differently to the same drug.

1. Two big pieces: pharmacokinetics and pharmacodynamics

Pharmacokinetics (what the body does to the drug) — the ADME processes that determine how much drug reaches target tissues and for how long.
Pharmacodynamics (what the drug does to the body) — how the drug interacts with molecules (usually proteins) to change cellular function and produce therapeutic (or adverse) effects.

Both sides must be understood to use medicines safely and effectively.

2. Absorption — how the drug enters the bloodstream

Routes of administration strongly influence absorption speed and extent:

Oral (by mouth) — convenient but variable. The drug must dissolve, survive stomach acid, cross the gut wall, and often pass through the liver before reaching the systemic circulation (first-pass effect).
Sublingual/buccal (under the tongue or cheek) — avoids most first-pass metabolism and can act faster.
Inhalation — rapid absorption into blood via lung alveoli (useful for bronchodilators, anesthetic gases).
Intravenous (IV) — delivers drug directly to blood; immediately 100% available.
Intramuscular or subcutaneous (IM/SC) — slower, depends on blood flow and formulation (depot injections are long-acting).
Topical/transdermal — applied to skin for local or systemic effect (patches rely on skin permeability).
Rectal, vaginal, ocular, intranasal — used when oral route is unsuitable or for local effects.

Key concepts

Bioavailability (F): fraction of administered dose reaching systemic circulation as active drug. IV = 100% (F = 1). Oral drugs often have lower F due to incomplete absorption and first-pass metabolism.
Rate vs. extent: Fast absorption gives rapid onset; extent determines total exposure.
Formulation matters: tablets, liquids, salts, enteric coatings, sustained-release systems all change absorption.

3. Distribution — how the drug moves through the body

Once in blood, drugs distribute into tissues. Distribution is not uniform.

Determinants of distribution

Blood flow to tissues: highly perfused organs (brain, liver, kidneys, heart) receive drug sooner than muscle or fat.
Capillary permeability and barriers: the blood–brain barrier tightly regulates entry into the brain; some tissues are “protected.”
Binding to plasma proteins (e.g., albumin): only unbound (free) drug crosses membranes and is pharmacologically active. Highly protein-bound drugs have lower free fractions but may act longer (since bound drug serves as a reservoir).
Fat solubility (lipophilicity): lipophilic drugs accumulate in fat and cell membranes; hydrophilic drugs stay in plasma and extracellular fluid.
Volume of distribution (Vd): a theoretical value that relates the amount of drug in the body to the concentration measured in plasma. Large Vd suggests extensive tissue uptake; small Vd means drug mostly in blood plasma.

Understanding distribution helps predict where a drug will act and how long it will persist.

4. Metabolism (biotransformation) — how the body changes drugs

The body chemically modifies many drugs, usually to inactivate them or to make them easier to excrete. The liver is the primary site, but metabolism can occur in the gut, lungs, kidneys, and other tissues.

Two general phases

Phase I (functionalization): reactions such as oxidation, reduction, or hydrolysis introduce or unmask functional groups (often via cytochrome P450 enzymes — CYPs). These reactions can reduce activity, convert prodrugs into active drugs, or form metabolites that are active or toxic.
Phase II (conjugation): combines the drug (or metabolite) with an endogenous molecule (e.g., glucuronic acid, sulfate, glutathione) to produce a water-soluble product ready for excretion.

Important issues

First-pass metabolism: orally ingested drugs may be extensively metabolized in the gut wall and liver before reaching systemic circulation — reducing bioavailability (e.g., many nitrates, some opioids).
Enzyme induction and inhibition: some drugs increase (induce) certain CYP enzymes over days–weeks, speeding metabolism of themselves or other drugs; others inhibit enzymes, raising levels of co-administered drugs and risking toxicity.
Genetic variability: inherited differences in drug-metabolizing enzymes (pharmacogenomics) can make people “fast” or “slow” metabolizers, affecting efficacy and safety.

5. Excretion — how drugs leave the body

The kidneys are the main excretory route for many drugs and metabolites; others are excreted in bile, sweat, saliva, or expired air.

Renal elimination pathways

Glomerular filtration — small unbound molecules filtered into urine.
Tubular secretion — active transporters in the proximal tubule secrete some drugs into urine (can be saturated).
Tubular reabsorption — lipid-soluble drugs may be reabsorbed back into blood; urine pH influences ionization and reabsorption (used clinically to enhance excretion of overdosed weak acids or bases).

Biliary excretion and enterohepatic recycling

Some drugs excreted into bile may be reabsorbed from the gut, prolonging their presence (enterohepatic recirculation).

6. Pharmacodynamics — how drugs produce effects

Drugs usually work by interacting with target molecules (receptors, enzymes, ion channels, transporters) to change cellular function.

Key ideas

Receptors and binding: drugs have affinity (how well they bind) and intrinsic activity (what they do after binding).
Agonists vs. antagonists: agonists activate receptors; antagonists bind without activating and block agonists.
Partial agonists: give intermediate activation even when fully occupying the receptor.
Dose–response relationship: increasing dose typically increases effect to a maximum (efficacy). The dose producing 50% of maximal effect is often a measure of potency.
Therapeutic window/index: the range between an effective dose and a dose that causes unacceptable toxicity. A narrow therapeutic index (e.g., warfarin, digoxin) requires careful monitoring.

7. Time courses — half-life, steady state, and dosing

Half-life (t½) is the time it takes for plasma concentration to fall by 50% during elimination. It depends on clearance and volume of distribution. Half-life helps determine:

Dosing intervals: drugs with short half-lives often need more frequent dosing.
Time to steady state: after regular dosing, steady state (where input equals elimination) is usually reached after about 4–5 half-lives.
Loading doses: a large initial dose can rapidly achieve target concentrations when a drug has a long half-life; maintenance doses maintain it.

Clearance (CL) is the volume of plasma cleared of drug per unit time. Dose = (desired concentration × CL) / bioavailability (for maintenance dosing).

8. Drug–drug and drug–food interactions

Interactions can change absorption, metabolism, distribution, or excretion:

Absorption: antacids can reduce absorption of some antibiotics; food can increase or decrease bioavailability.
Metabolism: inhibitors of CYP enzymes (e.g., certain antifungals, grapefruit juice) increase levels of substrates; inducers (e.g., some anticonvulsants) lower levels.
Protein displacement: two highly protein-bound drugs may compete, temporarily raising free concentrations of one.
Transporter interactions: drugs that block renal transporters can reduce clearance of others.

Clinically important interactions can lead to loss of efficacy or dangerous toxicity, so prescribers routinely check medication lists.

9. Sources of variability between patients

People respond differently to the same drug because of:

Age: newborns and the elderly have different absorption, metabolism, and excretion capacities.
Body composition: obesity changes distribution; low body weight affects dosing.
Genetics: variations in CYP enzymes, transporters, and receptors can alter drug responses.
Disease states: liver disease reduces metabolism; kidney disease reduces excretion.
Pregnancy: physiological changes alter volume of distribution and clearance; placenta and fetus add complexity.
Adherence and formulation: whether patients take medications correctly and whether the product is immediate or extended release.

Personalized dosing — considering these factors — improves safety and effectiveness.

10. Safety considerations and monitoring

Therapeutic drug monitoring (TDM): measuring blood levels for drugs with narrow therapeutic windows (e.g., lithium, vancomycin) helps keep concentrations in the safe and effective range.
Adverse drug reactions (ADRs): ranges from predictable, dose-dependent toxicities to unpredictable allergic or idiosyncratic reactions.
Medication errors and polypharmacy: multiple medications increase the risk of interactions and dose mistakes—especially in older adults.

Clear communication updated medication lists, and monitoring lab tests (liver, kidney, drug levels) reduce harm.

11. Putting it together: an example (oral antibiotic)

Take a common oral antibiotic as an example:

You swallow a pill (absorption). The tablet dissolves; the drug crosses the gut lining.
It passes through the liver (first-pass) where some is metabolized — reducing bioavailability.
The drug reaches blood, distributes well into lung tissue (good for pneumonia).
Liver enzymes slowly biotransform part of the molecule to a metabolite; the rest is excreted unchanged in urine.
The concentration at the infection site exceeds a minimum inhibitory concentration for a suitable time (pharmacodynamics), killing bacteria.
Because the drug is primarily renally excreted, dose reduction is required if kidney function is poor — illustrating how ADME informs dosing.

12. Why these principles matter for patients and clinicians

Understanding how medicines are absorbed, distributed, metabolized, and excreted helps explain:

Why some drugs must be taken multiple times a day while others are once-daily.
Why certain combinations are dangerous.
Why lab monitoring is necessary for specific treatments.
Why age, kidney or liver disease, or genetic differences change dosing.

These scientific principles guide safe prescribing, individualized therapy, and the development of new medicines.

Conclusion

Medicines are powerful because they reach target tissues and alter biological processes — but their effects depend on a chain of processes (ADME) and complex interactions with receptors and enzymes. Clinicians use concepts like bioavailability, half-life, clearance, and therapeutic index to design dosing that maximizes benefit and minimizes harm. For patients, following dosing instructions, informing prescribers about all medicines (including supplements), and attending monitoring appointments are practical steps to ensure medicines work as intended.

Sources

Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology. (textbook)
Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. (textbook)
Goodman & Gilman. The Pharmacological Basis of Therapeutics. (textbook)
U.S. Food and Drug Administration (FDA) — drug development and pharmacokinetics overview.
World Health Organization (WHO) — rational use of medicines and pharmacovigilance resources.
National Institute for Health and Care Excellence (NICE) and NHS (UK) patient information on medicines and monitoring.
Primary literature reviews on pharmacokinetics and pharmacodynamics (peer-reviewed journals).